Jefferies Financial Group Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC)
Equities researchers at Jefferies Financial Group started coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Get Free Report) in a report issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $135.00 price target on the biotechnology company’s stock. Jefferies Financial Group’s price target suggests a potential upside of 50.69% from the […]
Equities researchers at Jefferies Financial Group started coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Get Free Report) in a report issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $135.00 price target on the biotechnology company’s stock. Jefferies Financial Group’s price target suggests a potential upside of 50.69% from the […]
